Compare KOSS & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOSS | AYTU |
|---|---|---|
| Founded | 1953 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.8M | 27.4M |
| IPO Year | 1994 | 2015 |
| Metric | KOSS | AYTU |
|---|---|---|
| Price | $3.16 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 21.8K | ★ 23.1K |
| Earning Date | 10-29-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $13,020,773.00 | ★ $27,632,080.00 |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | N/A | $27.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.14 | ★ 277.47 |
| 52 Week Low | $3.18 | $1.80 |
| 52 Week High | $5.10 | $3.07 |
| Indicator | KOSS | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 27.89 | 44.96 |
| Support Level | N/A | $1.94 |
| Resistance Level | $4.14 | $2.34 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 4.20 | 25.00 |
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.